Last reviewed · How we verify
NCT04080102
Essential Amino Acids and High Intensity Interval Training
NA trial testing High Intensity Interval Training in Cardiovascular Risk Factor in 84 participants. Completed in 5 January 2020.
5 January 2020
Quick facts
| Lead sponsor | University of North Carolina, Chapel Hill |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 84 |
| Start date | 1 March 2019 |
| Primary completion | 5 January 2020 |
| Estimated completion | 5 January 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- High Intensity Interval Training
- Essential Amino Acid
- High intensity interval training and essential amino acid supplement
Conditions studied
- Cardiovascular Risk Factor — all drugs for Cardiovascular Risk Factor →
- Obesity — all drugs for Obesity →
Sponsor
University of North Carolina, Chapel Hill
Who can join
Adults 30 to 50, any sex, with Cardiovascular Risk Factor or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Purpose: The primary purpose is to determine the combined effects of essential amino acids (EAA) supplementation and high intensity interval training (HIIT) on body composition, muscle characteristics, and muscle architecture in overweight men and women over the course of eight weeks. A secondary purpose is to determine the metabolic effects of EAA supplementation and HIIT on whole body protein turnover, metabolic rate, substrate metabolism, and metabolomics. A tertiary purpose is to evaluate the modulatory effects of sex on body composition, metabolism, metabolic profile, cardiorespiratory fitness, and hunger and satiety in response to EAA supplementation and HIIT. Participants: Healthy overweight and obese men and women (30-50 years) Procedures (methods): In a block randomized design, 78 healthy, overweight or obese men and women will be randomized, to one of four, eight-week intervention groups using a 2:2:2:1 group allocation design: 1) essential amino acids (EAA) supplementation (7.2 grams EAA daily); 2) HIIT, two days per week of cycle ergometry training; 3) EAA + HIIT; or 4) control (CON), receiving no intervention. Measurements of body composition, muscle characteristics, resting metabolic rate, substrate metabolism, and cardiorespiratory fitness will be measured at baseline, 4-weeks, and 8-weeks. Metabolomics and whole body protein turnover will also be measured at baseline and 8-weeks. Subjects will be asked to arrive to testing sessions following a 12 hour fast (except for water), consuming no food, caffeine, or alcohol. Participants will also be asked to abstain from physical activity for 24 hours prior to testing. Subjects will complete one electronic contact (phone/email screening) and up to 22 in-person sessions (enrollment; 5 testing sessions \[2 at base, 1 at 4week, 2 at 8week\]; 16 training sessions \[for HIIT and EAA+HIIT\]) over the course of 8 weeks.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Metabolic effects of high-intensity interval training and essential amino acids.
Hirsch KR, Greenwalt CE, Cabre HE, Gould LM, et al · · 2021 · cited 12× · PMID 34427732 · DOI 10.1007/s00421-021-04792-4
Verify or expand the search:
- PubMed search for NCT04080102
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of High Intensity Interval Training
Trials testing the same drug.
- NCT07484399 — Comparing Effects of HIIT and MICT on Functional Mobility, Muscle Strength, and Quality of Life in Diabetic Patients · NA · not yet recruiting
- NCT07534293 — Effects of 7-Day Creatine Supplementation on Cognitive Function After High-Intensity Interval Training in Active Young M · NA · completed
- NCT07188272 — Effect of High-intensity Interval Training Combined With DASH Diet on Arterial Stiffness in Hypertensive Patients · NA · completed
- NCT06860256 — Different Exercise Training Programs in University Students with Primary Dysmenorrhea · NA · not yet recruiting
- NCT06621550 — Effect of High-Intensity Interval Training Exercise on Cognitive Function of Young Adults · NA · recruiting
Other recruiting trials for Cardiovascular Risk Factor
Currently open trials in the same condition.
- NCT07268781 — Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients · NA · active not recruiting
- NCT06225544 — Lumasiran in Hyperoxalaemic Patients on Haemodialysis · Phase 2 · recruiting
- NCT06372054 — TORNADO-Omics Techniques and Neural Networks for the Development of Predictive Risk Models · recruiting
- NCT05887622 — The Potassium Supplementation Study · NA · recruiting
- NCT04962061 — A Combined Multidomain Intervention to Prevent Cognitive Decline Associated With Cardiovascular Risk Factors. · NA · recruiting
Other University of North Carolina, Chapel Hill trials
Trials by the same sponsor.
- NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
- NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
- NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
- NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
- NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04080102 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
- Last refreshed: 30 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04080102.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing